方法：我院2009-10/2011-06的DR患者67例129眼，按其眼底病变程度分为早期和中期。将早、中期患者各分为试验组和对照组。其中早期病变的试验组为A1组(16例29眼)，对照组为A2组(14例26眼)； 中期病变的试验组为B1组(19例38眼)，对照组为B2组(18例36眼)。试验组服用羟苯磺酸钙及和血明目片3mo，对照组患者服用芦丁片，维生素C，肌苷片治疗。所有患者用药前后进行视力、眼压、散瞳眼底照相、眼底血管荧光造影，并进行对比分析。

结果：羟苯磺酸钙联合和血明目片治疗后，A1组较A2组眼底改善者明显，有效率明显增高(P<0.05)； B1组较B2组眼底改善者明显，有效率明显增高(P<0.05)； A1组较B1组眼底改善者明显，有效率高(P<0.05)。

结论：羟苯磺酸钙联合和血明目片对NPDR具有改善和稳定病变的作用，对早期病变疗效更为显著。

METHODS: Totally 67 diabetic patients 129 eyes were selected. Patients were divided into experimental group and control group. Nonage experimental group was named group A1(16 cases, 29 eyes), nonage control group was named group A2(14 eases, 26 eyes), metaphase experimental group was named group B1(19 cases, 38 eyes), and metaphase control group was named group B2(18 cases, 36 eyes). The patients in experimental group A1 and group B1 took domestic calcium dobesilate and hexuemingmu tablets for 12 weeks. The patients in control group A2 and B2 took rutin tablets, vitamin C and inosine tablets. Three months before and after treatment, the patients' vision, intraocular pressure, the condition of retina, FFA were observed and compared.

RESULTS: After treatment the number of patients with improvement of eye ground in group A1 was significantly more than that in group A2, so was the effective rate(P<0.05)in group B1 was significantly more than that in group B2, so was the effective rate(P<0.05)patients with improvement of eye ground in group A1 was significantly more than that in group B1, so was the effective rate(P<0.05)for early pathological changes.

CONCLUSION: Calcium dobesilate and hexuemingmu tablet is effective on NPDR, which is more obvious for early pathological changes.